表皮生长因子受体酪氨酸激酶家族与肿瘤治疗被引量：8

Epidermal growth factor receptor family tyrosine kinase and cancer therapy

下载PDF

导出

摘要表皮生长因子受体(EGFR,ErbB)酪氨酸激酶家族在多种肿瘤中有表达或高表达。在特异性配体的诱导下能够发生家族成员的二聚化,从而激活细胞内下游信号转导途径,调控细胞的增殖、分化、迁移等生物效应。异常的ErbB受体信号与肿瘤的发生、发展有着密切的关系。随着EGFR的人源化单抗Erbitux和针对EGFR的小分子抑制剂Tarceva的成功上市,以ErbB受体为靶点的抗肿瘤药物成为了近年来肿瘤治疗研究中的热点领域。 Overexpression of the tyrosine kinase level of epidermal growth factor receptor （EGFR, ErbB） family members caused human carcinomas. Upon binding to specific ligands, the ErbB receptors dimerize and then activate downstream signal transduction pathways that regulate multiple biological processes including cell proliferation, differentiation and migration. Aberrant ErbB receptor signals usually contribute to the progression and development of a number of human malignant tumors. Due to the successful launching of the recombinant humanized anti-EGFR monoclonal antibody Erbitux and the small molecular weight EGFR inhibitor Tarceva, anti-ERGF therapies have become one of the most promising fields for the development of selective therapies against cancers.

作者郭晓宁林莉萍章雄文丁健

机构地区中国科学院上海生命科学院上海药物研究所肿瘤药理实验室中国科学院研究生院

出处《中国新药杂志》 CAS CSCD 北大核心 2005年第10期1136-1140,共5页 Chinese Journal of New Drugs

关键词表皮生长因子受体肿瘤治疗酪氨酸激酶抑制剂 epidermal growth factor receptor cancer therapy tyrosine kinase inhibitor

分类号 R979.19 [医药卫生—药品] R977.3 [医药卫生—药品]

引文网络
相关文献

参考文献29

1[1]Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy[ J]. Oncogene, 2000,19(56) :6550 - 6565.
2[2]Yarden Y,Sliwkowski MX. Untangling the ErbB signaling network[ J ]. Nat Rev Mol Cell Biol,2001,2(2): 127 - 137.
3[3]Normanno N, Maiello MR, de Luca A. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) :simple drugs with a complex mechanism of action? [J]. J Cell Physiol, 2003, 194( 1 ):13 - 19.
4[4]Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression[J]. Exp Cell Res ,2003,284(1) :99 - 110.
5[5]Graus Porta D, Beerli RR, Daly JM, et al. ErbB-2, the preferred heterodimerization partner of all erbB receptors, is a mediator of lateral signaling[J]. EMBO J, 1997,16(7): 1647 - 1655.
6[6]Zvibel J, Brill S, Halpern Z, et al. Soluble and matrix-associated heparan sulfate proteoglycans increase expression of ErbB-2 and ErbB-3 in colon cancer cell lines[J]. Int J Cancer, 2001,91 (3) :316 -321.
7[7]Crovello CS,Lai C, Cantley LC, et al. Differential signaling by the epidermal growth factor-like growth factors neuregulin-1 and neuregulin-2 [ J ]. J Biol Chem, 1998,273 (41 ): 26954 - 26961.
8[8]Gamett DC, Pearson G, Cerione RA, et al. Secondary dimerization between members of the epidermal growth factor receptor family[J]. J Biol Chem, 1997,272(18): 12052 - 12056.
9[9]Zhang P, Wang YZ, Kagan E, et al. Peroxynitrite targets the epidermal growth factor receptor, Raf-1, and MEK independently to activate M APK[ J]. J Biol Chem, 2000,275 (29) :22479 - 22486.
10[10]Datta SR,Brunet A,Greenberg ME. Cellular survival:a play in three Akts[ J]. Genes Dev, 1999,13(22) :2905 - 2927.